Shandong Xinhua Pharmaceutical Company Limited
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shandong Xinhua Pharmaceutical Co., Ltd., as the core subsidiary of Hualu Holding Group Co., Ltd. in the pharmaceutical sector, was established in the Jiaodong Anti Japanese Base in 1943. It is the first chemical synthetic pharmaceutical enterprise in New China, an important global production and export base for antipyretic and analgesic drugs, and an important domestic production enterprise for cardiovascular, cerebrovascular, anti infective, central nervous system, and other related products. It has four pillar industries: chemical raw materials, pharmaceutical preparations, pharmaceutical intermediates, and pharmaceutical commercial logistics, six industrial parks, and 14 subsidiaries. The annual production capacity of chemical raw materials is 50000 tons, pharmaceutical intermediates are 500000 tons, solid preparations are 28 billion tablets (granules), small capacity injections are 1 billion tubes, and capsules are 1.5 billion capsules. The scale of leading raw materials such as ibuprofen, aspirin, and levodopa all ranks among the top in the world, with an annual export value of 300 million US dollars. We have established long-term strategic cooperation relationships with more than 100 well-known multinational enterprises such as Bayer, Bulgarino, and GlaxoSmithKline. We have 8 exclusive domestic varieties such as pipemidic acid and isopropylantipyrine, with a total asset of 7 billion yuan. We are one of the top 100 pharmaceutical industry enterprises, one of the top five raw material drug export enterprises, and one of the top ten pharmaceutical export enterprises in China. Xinhua Pharmaceutical is an H-share and A-share listed company, and the Xinhua brand trademark is listed as a key export brand for cultivation and development by the Ministry of Commerce and Shandong Province. Xinhua Pharmaceutical is a national high-tech enterprise, a key high-tech enterprise of the National Torch Plan, and a backbone enterprise of the National Torch Plan Biomedical Industry Base. It has a national enterprise technology center and six talent platforms, including academician workstation, postdoctoral workstation, Mount Taishan industrial talent post, Mount Taishan scholar post, master joint training center, and Shandong technician workstation. In recent years, Xinhua Pharmaceutical has increased its cooperation between schools and enterprises, collaborating with the Chinese Academy of Medical Sciences, Shenyang Pharmaceutical University, China Pharmaceutical University, Tsinghua University, Shandong University, and others to promote innovative drug research and development. On the basis of consolidating its traditional advantages, the company focuses on drugs such as cardiovascular, cerebrovascular, digestive system, anti-tumor, anti-metabolic, central nervous system, and anti infective drugs, increases research and development investment, and lays out more than 100 new products. A total of 16 products and 22 specifications have passed the national drug quality consistency evaluation. Currently, it has 8 national Class I new drug registration numbers and 21 Class II new drug registration numbers, and has obtained more than 260 authorized patents. It is a three-star "Chinese Patent Shandong Star Enterprise" (the highest level). The quality values of "product quality is related to the life of enterprises, and drug quality is related to the life of people" of Xinhua Pharmaceutical have been deeply implemented by all staff and the entire process. The company focuses on quality investment and has established a quality control system throughout the entire process from raw material entry, production, to product delivery. In the 1990s, Xinhua Pharmaceutical was one of the first batch to receive the "Excellent Quality Management Award" in China. 23 products have successively won the provincial and ministerial level or above high-quality product awards, including 3 products winning the National Gold Award, 3 products winning the National Silver Award, and multiple products winning the Shandong Province Famous Brand Product Award. At present, all drugs produced by Xinhua Pharmaceutical have passed the new national GMP certification, 16 products have passed FDA inspections in the United States, 10 products have obtained the EU COS certificate, and the preparation workshop has passed MHRA and FDA audits. Xinhua brand formulations are exported to the US market, becoming one of the first batch of 15 leading enterprises in implementing the internationalization strategy of formulations and one of the top ten enterprises in China's formulation export. In recent years, Xinhua Pharmaceutical has launched a number of new drugs, such as: the national first class innovative drug, a new non hormone anti-inflammatory and anti allergic drug - Adit (Ethoxybenzamide Ointment), a cutting-edge drug for the treatment of stomach diseases - Zoletide (Rabeprazole Sodium Enteric coated Tablets), Jiaheluo (Glimepiride Tablets) for the treatment of diabetes, Jiening (Aspirin Enteric coated Sustained release Tablets) for the treatment of cardiovascular and cerebrovascular drugs The main products of the national 3.1 new drug Baochang (Polycarbofulfacalcium Tablets) and the unique dosage form of Nimodipine sustained-release capsules are listed in the national medical insurance catalog. As a state-owned holding enterprise with a red gene, for many years, the company has emphasized the strengthening of quality, internationalization, technology, and responsibility connotations, and created professional characteristics through comprehensive means. It has established a good image of quality Xinhua, international Xinhua, technology Xinhua, and responsibility Xinhua, and has become a national model enterprise for harmonious labor relations, one of the top 100 enterprises in Chinese enterprise education, a national green factory and green supply chain enterprise, and a leading enterprise in Shandong Province's science and technology Exemplary organization for Talent Work in Shandong Province, Top 100 Foreign Trade Enterprises in Shandong Province, Advanced Enterprise for Safe Production in Shandong Province, the first batch of five-star brand enterprises of "Honest Shandong Merchants" in Shandong Province, and the advanced collective of Shandong Province in fighting against COVID-19. |
| Headquarter | Zibo |
| Establish Date | 11/20/1998 |
| Listed Code | 000756.SZ |
| Listed Date | 8/6/1997 |
| Chairman | He Tongqing. |
| CEO | Xu Wenhui. |
| Website | www.xhzy.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
